ZUMILOKIBART
UNII QGU9EYX5RE

Substance Identification & Data

This profile provides standardized clinical and technical data for Zumilokibart, uniquely identified by the FDA Unique Ingredient Identifier (UNII) QGU9EYX5RE.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3037408-64-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

QGU9EYX5RE

CAS Registry Number

3037408-64-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

ZUMILOKIBART

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C223321

National Cancer Institute reference terminology for clinical and research data.

INN ID

13638

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

OP-167

Identifier assigned by the United States Adopted Names Council.

Substance Type

Zumilokibart

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Zumilokibart. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Zumilokibart

Common Names & Synonyms

H-gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV4-4*08 (77.1%) -(IGHD) -IGHJ5*01 (84.6%) L123>T (113), CDR-IMGT [8.7.12] (26-33.51-57.96-107)) (1-118) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 6-G1-v14 CH2 A1.3, A1.2, 9-G1v21 CH2 Y15.1, T16, E18 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 L1.3>A (235), L1.2>A (236), M15.1>Y (253), S16>T (255), T18>E (257) (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-218')-disulfide with L-kappa light chain humanized (1'-218') [V-KAPPA (Homo sapiens IGKV1-9*03 (83.7%) -IGKJ4*01 (100%), CDR-IMGT [10.3.9] (27'-36'.54'-56'.93'-101')) (1'-111') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (157'), V101 (195')) (112'-218')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

Immunoglobulin G1 [235-alanine,236-alanine,253-tyrosine,255-threonine,257-glutamic acid], anti-(human interleukin 13) (human-Mus musculus monoclonal APG777 γ1-chain), disulfide with human-Mus musculus monoclonal APG777 κ-chain, dimer

Immunoglobulin G1-kappa, anti-[Homo sapiens IL13 (interleukin-13)], humanized monoclonal antibody; H-gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV4-4*08 (77.1%) (IGHD) -IGHJ5*01 (84.6%) L123>T (113), CDR-IMGT [8.7.12] (26-33.51-57.96-107)) (1-118) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 6-G1-v14 CH2 A1.3, A1.2, 9-G1v21 CH2 Y15.1, T16, E18 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 L1.3>A (235), L1.2>A (236), M15.1>Y (253), S16>T (255), T18>E (257) (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-218')-disulfide with L-kappa light chain humanized (1'-218') [V-KAPPA (Homo sapiens IGKV1-9*03 (83.7%) -IGKJ4*01 (100%), CDRIMGT [10.3.9] (27'-36'.54'-56'.93'-101')) (1'-111') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (157'), V101 (195')) (112'-218')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

ZUMILOKIBART [USAN]

immunoglobulin G1-kappa, anti-[Homo sapiens IL13 (interleukin-13)], humanized monoclonal antibody

zumilokibart [INN]